

Resource Summary Report

Generated by [NIF](#) on Sep 10, 2026

MDST8

RRID:CVCL_2588

Type: Cell Line

Proper Citation

RRID:CVCL_2588

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2588

Proper Citation: RRID:CVCL_2588

Description: Cell line MDST8 is a Cancer cell line with a species of origin Homo sapiens (Human)

Disease: Colon carcinoma

Defining Citation: [PMID:9813657](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25926053](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:28854368](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: MDST8

Synonyms: T8

Cross References: CLO:CLO_0009970, EFO:EFO_0006644, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioGRID_ORCS_Cell_line:550, BioSample:SAMN03473139, BioSample:SAMN10988016, cancercellines:CVCL_2588, Cell_Model_Passport:SIDM00527, ColonAtlas:MDST8, Cosmic:1995502, Cosmic-CLP:1240173, DepMap:ACH-000935, ECACC:99011801, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, GDSC:1240173, GEO:GSM206524, GEO:GSM827347, GEO:GSM887303,

GEO:GSM888378, GEO:GSM1448122, GEO:GSM1670088, IARC_TP53:30118, LiGeA:CCLE_843, LINCS_LDP:LCL-1164, PharmacnoDB:MDST8_908_2019, PRIDE:PXD005235, PRIDE:PXD030304, Progenetix:CVCL_2588, Wikidata:Q54904834

ID: CVCL_2588

Record Creation Time: 20220427T220758+0000

Record Last Update: 20260905T181128+0000

Ratings and Alerts

No rating or validation information has been found for MDST8.

No alerts have been found for MDST8.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Morozova V, et al. (2025) Pharmacodynamic analyses of LAT1 inhibitors in vitro and in vivo by targeted metabolomics reveal target-independent effects. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie*, 190, 118402.

Asif PJ, et al. (2025) Mesenchymal Colorectal Cancers Secrete Vesicles With Unique Cargo That Can Be Used for Liquid Biopsy Based Diagnostics. *Journal of extracellular vesicles*, 14(11), e70171.

Castro J, et al. (2025) A Potent, Selective, Small-Molecule Inhibitor of DHX9 Abrogates Proliferation of Microsatellite Instable Cancers with Deficient Mismatch Repair. *Cancer research*, 85(4), 758.

Sogari A, et al. (2024) Tolerance to colibactin correlates with homologous recombination proficiency and resistance to irinotecan in colorectal cancer cells. *Cell reports. Medicine*, 5(2), 101376.

Pacini C, et al. (2024) A comprehensive clinically informed map of dependencies in cancer cells and framework for target prioritization. *Cancer cell*, 42(2), 301.

Bootsma S, et al. (2024) Exploiting a subtype-specific mitochondrial vulnerability for successful treatment of colorectal peritoneal metastases. *Cell reports. Medicine*, 5(5), 101523.